Effects of GLYN122 on Motor Behavior in R6/2 Mice of Huntington’s Disease

The objective of this study was to investigate the effects of GLYN122 on body weight and motor deficits in transgenic R6/2 mice of Huntington’s disease. Total of 20 female and male R6/2 mice and 10 female and male wild-type littermate control mice (WT) were used in the study. The mice were genotyped and the R6/2 mice were divided into different treatment groups based on their litter and baseline body weight. The treatment with Vehicle or GLYN122 (33 mg/kg; 5 ml/kg, i.p. QD) was started at 4 weeks of age after the baseline behavioral tests. Body weights were measured at 3 weeks of age and twice a week until the end of the study. Motor function testing using rotarod were commenced at 4 weeks (pre-treatment baseline) and continued at 6, 8 and 10 weeks of age, accompanied with grip strength at 4 (pre-treatment baseline), 10 and 12 weeks of age. At the end point of 12 weeks of age the mice were subjected to tissue collection, and the brain samples were used for immunohistochemical analyses. You will find here the full set of the animal research data deposited.本研究旨在探究GLYN122对亨廷顿舞蹈病（Huntington’s disease）转基因R6/2小鼠的体重与运动功能缺陷的影响。本研究共使用20只雌雄R6/2小鼠与10只雌雄野生型同窝对照小鼠（WT）。研究人员对所有小鼠完成基因分型后，依据同窝信息与基线体重将R6/2小鼠分为不同给药组。在基线行为学测试结束后，于小鼠4周龄时开始给予赋形剂（Vehicle）或GLYN122（33 mg/kg；5 ml/kg，腹腔注射(i.p.)，每日一次(QD)）。分别于3周龄时及之后每周两次测量小鼠体重，直至实验结束。采用转棒实验（rotarod）开展运动功能测试：于4周龄（给药前基线）启动测试，并分别在6、8、10周龄持续进行；抓力测试则于4周龄（给药前基线）、10及12周龄时开展。在实验终点12周龄时，对小鼠进行组织采集，脑组织样本用于免疫组织化学分析。本数据集包含本次动物研究的全部存档实验数据。